Cargando…

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

INTRODUCTION: This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without adjuvant in patients with mild Alzheimer's disease. METHODS: One hundred twenty-one patients received up to seven intramuscular injections of C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandenberghe, Rik, Riviere, Marie-Emmanuelle, Caputo, Angelika, Sovago, Judit, Maguire, R. Paul, Farlow, Martin, Marotta, Giovanni, Sanchez-Valle, Raquel, Scheltens, Philip, Ryan, J. Michael, Graf, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651373/ https://www.ncbi.nlm.nih.gov/pubmed/29067316 http://dx.doi.org/10.1016/j.trci.2016.12.003

Ejemplares similares

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
por: Farlow, Martin R, et al.
Publicado: (2015)

Active immunotherapy options for Alzheimer’s disease
por: Winblad, Bengt, et al.
Publicado: (2014)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
por: Voss, Tiffini, et al.
Publicado: (2018)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

An amylin analog used as a challenge test for Alzheimer's disease
por: Zhu, Haihao, et al.
Publicado: (2017)

Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
por: Langlois, Carolyn M., et al.
Publicado: (2019)

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study
por: Jutten, Roos J., et al.
Publicado: (2017)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
por: Langbaum, Jessica B., et al.
Publicado: (2020)

Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease
por: Schott, Jonathan M., et al.
Publicado: (2016)

Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
por: Caputo, Angelika, et al.
Publicado: (2023)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes
por: Malpetti, Maura, et al.
Publicado: (2020)

Intranasal rifampicin for Alzheimer's disease prevention
por: Umeda, Tomohiro, et al.
Publicado: (2018)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Estrogen activates Alzheimer's disease genes
por: Ratnakumar, Abhirami, et al.
Publicado: (2019)

Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
por: Boada, Mercè, et al.
Publicado: (2021)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Progranulin mutations in clinical and neuropathological Alzheimer's disease
por: Vardarajan, Badri N., et al.
Publicado: (2022)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Dissociation of Down syndrome and Alzheimer's disease effects with imaging
por: Matthews, Dawn C., et al.
Publicado: (2016)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

Alzheimer's‐like signaling in brains of COVID‐19 patients
por: Reiken, Steve, et al.
Publicado: (2022)

Midlife lipid and glucose levels are associated with Alzheimer's disease
por: Zhang, Xiaoling, et al.
Publicado: (2022)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Alzheimer's disease Archimedes condition-event simulator: Development and validation
por: Kansal, Anuraag R., et al.
Publicado: (2018)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Measuring informed consent capacity in an Alzheimer's disease clinical trial
por: Guarino, Peter D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h5hjc331r7jtu96qpumda0t6dg